Topiramate Capsule, Extended Release
Product Images NDC 68382-358

7 FDA label images from Zydus Pharmaceuticals Usa Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 68382-358). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (2df80400 Fa1a 4bda 8654 5e0ce5844de4 01)

Image (2df80400 Fa1a 4bda 8654 5e0ce5844de4 01)
Chemical structure of topiramate, showing its molecular arrangement with multiple oxygen, sulfur, and carbon atoms arranged in a ring system with attached functional groups.*
FDA Label Image

Image (2df80400 Fa1a 4bda 8654 5e0ce5844de4 02)

Image (2df80400 Fa1a 4bda 8654 5e0ce5844de4 02)
A cumulative rate graph comparing Time to First Seizure for Topiramate at 50 mg/day and 400 mg/day over approximately 500 days, showing a higher cumulative rate for the 50 mg/day group. The x-axis represents time in days and the y-axis represents cumulative rates for the event.*
FDA Label Image

Image (2df80400 Fa1a 4bda 8654 5e0ce5844de4 03)

Image (2df80400 Fa1a 4bda 8654 5e0ce5844de4 03)
A bar chart comparing the change from baseline to double-blind phase in average monthly migraine period rate (with standard error) across placebo and topiramate doses (50 mg/day, 100 mg/day, 200 mg/day) from two studies. The chart shows decreasing migraine rates with increasing topiramate doses, with markers indicating statistical significance at p<0.10 and p<0.001 levels.*
FDA Label Image

25 mg (2df80400 Fa1a 4bda 8654 5e0ce5844de4 04)

25 mg (2df80400 Fa1a 4bda 8654 5e0ce5844de4 04)
Label for Topiramate Extended-Release Capsules USP, 25 mg, by Zydus Pharmaceuticals USA Inc. The oral dosage form is an extended-release capsule, once daily. The package contains 30 capsules and is labeled Rx only. The label includes storage instructions, child-resistant packaging note, and manufacturer information from Zydus Lifesciences Ltd. in India.*
FDA Label Image

50 mg (2df80400 Fa1a 4bda 8654 5e0ce5844de4 05)

50 mg (2df80400 Fa1a 4bda 8654 5e0ce5844de4 05)
Label for Topiramate Extended-Release Capsules USP 50 mg by Zydus Pharmaceuticals USA Inc. The label shows the dosage form as once daily extended-release capsules with a 30 capsule count. It includes storage instructions, child-resistant packaging notice, and manufacturer and distributor details. The package warns to swallow capsules whole without crushing or chewing.*
FDA Label Image

100 mg (2df80400 Fa1a 4bda 8654 5e0ce5844de4 06)

100 mg (2df80400 Fa1a 4bda 8654 5e0ce5844de4 06)
Topiramate 100 mg extended-release capsules label by Zydus Pharmaceuticals USA Inc. This prescription oral capsule is packaged in a container of 30 capsules. The label includes directions to swallow capsules whole, storage instructions, child-resistant packaging notice, and distributor information for Zydus Pharmaceuticals USA Inc.*
FDA Label Image

200 mg (2df80400 Fa1a 4bda 8654 5e0ce5844de4 07)

200 mg (2df80400 Fa1a 4bda 8654 5e0ce5844de4 07)
Label for Topiramate Extended-Release Capsules, USP, 200 mg strength. The label states the product is for once daily oral use, contains 30 capsules, and is manufactured by Zydus Pharmaceuticals USA Inc. It includes instructions to swallow the capsule whole and notes the package is child-resistant. Storage and dispensing details are also provided along with a barcode and NDC 68382-358-06.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.